Project Details
Description
Project Narrative
Engineered antibodies present a new treatment modality for viruses to circumvent major obstacles
presented by the existence of various serotypes in certain viruses, and to address the development
of engineered antibodies that can cross-react related viruses. These two applications are the focus
of this interdisciplinary proposal, where a computational residue-based pharmacophore description
of the monoclonal antibody interface is used to direct phage display experiments in order to identify
broadly neutralizing or cross-reacting antibodies against dengue and Zika viruses.
Status | Active |
---|---|
Effective start/end date | 11/15/18 → 10/31/23 |
Funding
- National Institute of Allergy and Infectious Diseases: $345,444.00
- National Institute of Allergy and Infectious Diseases: $417,500.00
- National Institute of Allergy and Infectious Diseases: $417,500.00
- National Institute of Allergy and Infectious Diseases: $72,056.00
- National Institute of Allergy and Infectious Diseases: $417,500.00
- National Institute of Allergy and Infectious Diseases: $417,500.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.